Summit Therapeutics (SMMT) cash on hand

Cash · fiscal 2025
$713.45M

Summit Therapeutics (SMMT) held cash of $713.45M at the end of fiscal 2025 (December 31, 2025). That is 73.0% higher than the $412.35M of fiscal 2024. Figures as of 18 Nov 2026, 04:57 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Cash, fiscal 2025
$713.45M
Change on fiscal 2024
+73.0%
Highest on record
$713.45Mfiscal 2025
Lowest on record
$186.24Mfiscal 2023
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Summit Therapeutics cash on hand, in more detail

Across the 4 fiscal years on record (2022–2025), the highest was $713.45M in fiscal 2025 and the lowest $186.24M in fiscal 2023.

History · 4 fiscal years

Cash by fiscal year

Summit Therapeutics cash on hand, year by year

Summit Therapeutics (SMMT) cash on hand by fiscal year
Fiscal yearCashChangeYear ended
2025$713.45M 73.0% up
2024$412.35M 121.4% up
2023$186.24M 46.6% down
2022$348.61M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.

How to read it

Cash is the cushion that pays for bad years, buybacks and acquisitions; compare it with total debt to see whether the company is a net borrower.

Cash at health care companies of similar size

Cash of Summit Therapeutics and comparable companies
CompanyCashFiscal year
BridgeBio Pharma BBIO$587.48M2025
Summit Therapeutics SMMT$713.45M2025
Glaukos GKOS$278.76M2025
Encompass Health EHC$72.20M2025
BrightSpring Health Services BTSG$88.37M2025
Baxter International BAX$1.97B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on SMMT

Summit Therapeutics, figure by figure

Summit Therapeutics (SMMT) overview: price, valuation and scorecardAll health care companies by market value

Summit Therapeutics cash on hand: questions and answers

How much cash does Summit Therapeutics have?

Summit Therapeutics (SMMT) held cash of $713.45M at the end of fiscal 2025 (December 31, 2025). That is 73.0% higher than the $412.35M of fiscal 2024.

What are the highest and lowest cash figures on record for Summit Therapeutics?

Across the 4 fiscal years on record (2022–2025), the highest was $713.45M in fiscal 2025 and the lowest $186.24M in fiscal 2023.

How is Summit Therapeutics's cash calculated?

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Summit Therapeutics (SMMT) cash on hand”, data as of 18 November 2026. https://funkfolio.com/stock/SMMT/cash

Underlying data: the company's filings with the SEC and Yahoo Finance.